Energenesis Biomedical CO.,LTD. Company Description

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control.

The company also offers scientific products, which include western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions.

Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.

Energenesis Biomedical CO.,LTD.

Country	Taiwan
Founded	2012
Industry	Biotechnology
Sector	Healthcare
Employees	35
CEO	Han-min Chen

Contact Details

Address: No.21, Ln.583, Ruiguang Road Taipei, 11492 Taiwan
Phone	886 2 2627 0835
Website	energenesis-biomedical.com

Stock Details

Ticker Symbol	6657
Exchange	Taiwan Stock Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006657000
SIC Code	2834

Key Executives

Name	Position
Dr. Han-min Chen	Co-Founder, Chief Executive Officer, Chairman and GM
Jen-yi Chiu	Co-Founder
Pei-chao Chen	Head of Accounting
Dr. Lin Juncai	Senior Vice President and Head of Research & Development Center
Ming-tsan Chiang	Vice President, Corporate Governance Officer and Director of the General Administrative Division
Chueh-Hua Kuo	Chief Internal Auditor
Chen Jiafu	Deputy General Manager and Head of Business Center
Jiang Mingcan	GM, Head of the Accounting and Administration Center and Head of Corporate Governance